The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Distaclor LA Forte 500 mg prolonged release tablets

Flynn Pharma LtdPA1226/001/005

Main Information

Trade NameDistaclor LA Forte 500 mg prolonged release tablets
Active SubstancesCefaclor monohydrate
Dosage FormProlonged-release tablet
Licence HolderFlynn Pharma Ltd
Licence NumberPA1226/001/005

Group Information

ATC CodeJ01DC Second-generation cephalosporins
J01DC04 cefaclor


Licence Issued16/06/1994
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back